Display Settings:

Format

Send to:

Choose Destination
    J Biol. 2009;8(3):30. Epub 2009 Apr 15.

    Exploiting the promiscuity of imatinib.

    Source

    Department of Medicine and Division of Hematology-Oncology, 3855 Health Sciences Drive, University of California-San Diego, La Jolla, CA 92093, USA.

    Erratum in

    • J Biol. 2010;8:82.

    Abstract

    The protein kinase inhibitor imatinib, also known as Gleevec, has been a notable success in treating chronic myelogenous leukemia. A recent paper in BMC Structural Biology reports a 1.75 A crystal structure of imatinib bound to the oxidoreductase NQO2 and reveals insights into the binding specificity and the off-target effects of the inhibitor.

    PMID:
    19435483
    [PubMed - indexed for MEDLINE]
    PMCID: PMC2689438
    Free PMC Article

    Images from this publication.See all images (2) Free text

    Figure 2
    Figure 1

      Supplemental Content

      Click here to read Click here to read

      Chemical compound information

      See 7 citations for this compound....

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk